Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Codexis (CDXS) Other financing activities (2010 - 2025)

Codexis' quarterly Other financing activities came in at $3000.0 in Q2 2025, down 98.34% year-on-year from $181000.0 in Q2 2024, and down 98.34% quarter-over-quarter from $181000.0 in Q2 2024.

Codexis has reported Other financing activities for 9 years, with the latest figure at $3000.0 in Q2 2025.

  • For the quarter ending Q2 2025, Other financing activities fell 98.34% year-over-year to $3000.0; the trailing twelve-month figure through Dec 2025 stood at $3000.0 (down 99.53% YoY), and the FY2025 full-year result was $3000.0, down 99.53% from the prior year.
  • Other financing activities for Q2 2025 stood at $3000.0, down from $181000.0 in the prior quarter.
  • The five-year high for Other financing activities was $461000.0 in Q1 2024, with the low at -$42000.0 in Q4 2022.
  • Average Other financing activities over 4 years is $121714.3, with a median of $54000.0 recorded in 2021.
  • Year-over-year, Other financing activities sank 177.78% in 2022 and tumbled 98.34% in 2025.
  • Tracing CDXS's Other financing activities over 4 years: stood at $54000.0 in 2021, then slumped by 177.78% to -$42000.0 in 2022, then surged by 530.95% to $181000.0 in 2024, then plunged by 98.34% to $3000.0 in 2025.
  • The last three Other financing activities figures came in at $3000.0 (Q2 2025), $181000.0 (Q2 2024), and $461000.0 (Q1 2024), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn -
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn -
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn -
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn -
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn
7 Evaxion A 64.16 Bn 64.14 Bn -
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn
10 Codexis 251.43 Mn 186.29 Mn 13.18 Mn

Historic Data

Download Data 🔒
DateValue
Jun 30, 2025 3,000.00
Jun 30, 2025 3,000.00
Jun 30, 2024 181,000.00
Jun 30, 2024 181,000.00
Mar 31, 2024 461,000.00
Mar 31, 2024 461,000.00
Dec 31, 2022 -42,000.00
Dec 31, 2022 -42,000.00
Mar 31, 2022 42,000.00
Mar 31, 2022 42,000.00
Dec 31, 2021 54,000.00
Dec 31, 2021 54,000.00
Sep 30, 2021 153,000.00
Sep 30, 2021 153,000.00
Dec 31, 2020 5.20 Mn
Dec 31, 2020 5.20 Mn
Dec 31, 2019 -6,000.00
Dec 31, 2019 -6,000.00
Sep 30, 2019 129,000.00
Sep 30, 2019 129,000.00
Jun 30, 2019 100,000.00
Jun 30, 2019 100,000.00
Sep 30, 2018 180,000.00
Sep 30, 2018 180,000.00
Sep 30, 2017 62,000.00
Sep 30, 2017 62,000.00
Sep 30, 2010 764,000.00
Sep 30, 2010 764,000.00